University of Minnesota. Driven to Discover.
An alarming number of countries are reporting cases, as clinicians find more links to microcephaly and other neurologic complications.
Also, more vaccine details emerge, including a candidate that might be available for emergency use this year.
Seven outbreak countries are seeing a rise in microcephaly or Guillain-Barre disease.
The WHO's top drug and development official projected the launch of a large vaccine trial is still at least 18 months away, but a test might be available within weeks.
Also, Brazil's health ministry rejected a possible microcephaly link to larvicides, and experts are gathering for a US Zika priority workshop tomorrow.
CDC guidance now excludes destinations above 6,500 feet, as Aedes mosquitoes are rare in those areas.
Study says 2.2 billion people live in areas suitable for Zika spread, and over the next year more than 5 million babies will be born in vulnerable parts of the Americas.
In other developments, a transgenic mosquito project is in the works for Grand Cayman and Spain reported a travel-linked microcephaly case.
Other new reports detail co-infections with other mosquito-borne viruses and fatal encephalitis.
Sort Results By:
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
Become an underwriter»
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.